ELMD Stock Forecast: Electromed, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Electromed, Inc. is $49. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 89 of 100 as at 21 Nov 2026 — inside the top quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Electromed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (25): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ELMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ELMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Aug 2026 | Lake Street | Maintains | Buy | — |
| 13 May 2026 | B. Riley Securities | Maintains | Buy | — |
| 12 Feb 2026 | Freedom Broker | Maintains | Buy | — |
| 19 Nov 2025 | Freedom Broker | Maintains | Buy | — |
| 13 Nov 2025 | Roth Capital | Reiterates | Buy | — |
| 27 Aug 2025 | Lake Street | Assumes | Buy | $36 |
| 27 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 22 July 2025 | Roth Capital | Initiates | Buy | — |
| 20 Feb 2025 | B. Riley Securities | Initiates | Buy | — |
| 11 May 2023 | EF Hutton | Reiterates | Buy | — |
| 16 Feb 2023 | EF Hutton | Maintains | Buy | — |
| 15 Feb 2023 | Lake Street | Maintains | Buy | — |
| 28 Dec 2022 | Lake Street | Assumes | Buy | $20 |
| 6 Sept 2022 | EF Hutton | Initiates | Buy | — |
| 5 Aug 2022 | Lake Street | Initiates | Buy | — |
| 24 Nov 2020 | Northland Capital Markets | Initiates | Outperform | — |
| 18 Oct 2019 | Dougherty & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELMD.
This page is one stock. Monday covers all of them.
ELMD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ELMD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Electromed, Inc. returned −8.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ELMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 16.7×
- Price / sales
- 2.5×
- Price / book
- 3.6×
- EV / EBITDA
- 11.2×
Cheaper than 52% of US stocks
Cheaper than 42% of US stocks
Cheaper than 26% of US stocks
Cheaper than 51% of US stocks
- Revenue growth (YoY)
- 10.6%
- Earnings growth (YoY)
- 29.3%
- Gross margin
- 78.7%
- Operating margin
- 19.5%
- Net margin
- 15.8%
Higher than 55% of US stocks
Higher than 66% of US stocks
Higher than 90% of US stocks
Higher than 79% of US stocks
Higher than 77% of US stocks
- Return on equity
- 24.5%
- Return on assets
- 16.0%
- Dividend yield
- —
Higher than 85% of US stocks
Higher than 97% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Electromed, Inc. has a market value of $190.1M and an enterprise value of $174.3M.
Revenue in the twelve months to 30 June 2026: $73.8M. The latest quarter grew 11.6% year on year.
Net income over the same four quarters: $11.3M, a 15.3% net margin.
Diluted earnings per share, trailing twelve months: $1.31.
Free cash flow in the twelve months to 30 June 2026: $8.4M, after $1.3M of capital spending.
Electromed, Inc. spent $3.9M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 16.7×; forward P/E: 37.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Electromed, Inc. employs 195 people — $378K of revenue per employee.
Data provided by Twelve Data
ELMD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ELMD’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Electromed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ELMD
What is the ELMD stock price forecast for 2026-2027?
The median 12-month analyst price target for Electromed, Inc. is $49, with estimates ranging from $47 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ELMD stock a buy right now?
Of the 2 analysts covering Electromed, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Electromed, Inc. 89 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ELMD?
As at 21 Nov 2026, Electromed, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
Will ELMD stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $49, and Ticker Nerd's factor model ranks Electromed, Inc. 89 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ELMD stock forecast for 2030?
No analyst covering Electromed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $50 over the next 12 months.
How has ELMD stock performed over the past year?
Electromed, Inc. returned -8.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Electromed, Inc. do?
Electromed, Inc. is a medical device company focused on airway clearance therapy for patients with compromised pulmonary function. The company develops, manufactures, markets, and sells the SmartVest airway clearance system and related products that use high frequency chest wall oscillation (HFCWO) to help mobilize airway secretions.
About Electromed, Inc.
Electromed, Inc. is a medical device company focused on airway clearance therapy for patients with compromised pulmonary function. The company develops, manufactures, markets, and sells the SmartVest airway clearance system and related products that use high frequency chest wall oscillation (HFCWO) to help mobilize airway secretions. Its portfolio includes home-use therapy systems as well as products designed for acute care settings, serving patients with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Electromed also offers connected therapy solutions that support communication between patients and physicians and help monitor treatment use. Headquartered in New Prague, Minnesota, Electromed plays a specialized role in respiratory care by providing noninvasive airway management tools used by clinicians, patients, and healthcare providers in the United States and selected international markets.
CEO Mr. James L. Cunniff · 195 employees · United States · https://smartvest.com